New pill aims to tame ulcerative colitis Flare-Ups

NCT ID NCT07265570

Recruiting now Disease control Sponsor: InSilico Medicine Hong Kong Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests an experimental pill called ISM5411 (Garutadustat) in 80 adults with active ulcerative colitis. Half receive the drug, half a placebo, and neither patients nor doctors know who gets what. The goal is to check if the drug is safe and helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ISM5411 (Garutadustat) tablets
What this could lead to: If successful, this could point toward a new oral treatment option for people with active ulcerative colitis.
What could go wrong: This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Beijing Friendship Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, China
Binzhou Medical University Hospital
RECRUITING

Binzhou, Shandong, China
First Hospital of Shanxi Medical University
RECRUITING

Taiyuan, Shanxi, China
Guangzhou First People's Hospital
RECRUITING

Guangzhou, Guangdong, China
Huizhou First Hospital
RECRUITING

Huizhou, Guangdong, China
Lishui Central Hospital
RECRUITING

Lishui, Zhejiang, China
Longhua Hospital Shanghai University of Traditional Chinese Medicine
RECRUITING

Shanghai, Shanghai Municipality, China
Meihekou Central Hospital
RECRUITING

Tonghua, Jilin, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, China
Renmin Hospital of Wuhan University
RECRUITING

Wuhan, Hubei, China
Shengjing Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, China
Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, China
Tai 'an City Central Hospital
RECRUITING

Taian, Shandong, China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Gannan Medical University
RECRUITING

Ganzhou, Jiangxi, China
The First Affiliated Hospital of Henan University of Science & Technology
RECRUITING

Luoyang, Henan, China
The First Affiliated Hospital of Kunming Medical University
RECRUITING

Kunming, Yunnan, China
The First Affiliated Hospital of University of South China
RECRUITING

Hengyang, Hunan, China
The First Affiliated Hospital of Xinxiang Medical University
RECRUITING

Xinxiang, Henan, China
The First Affiliated Hospital,Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, China
The People's Hospital of Guangxi Zhuang Autonomous Region
RECRUITING

Nanning, Guangxi, China
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, Zhejiang, China
The Second Hospital of HeBei Medical University
RECRUITING

Shijiazhuang, Hebei, China
The Third Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, China
Tianjin People's Hospital
RECRUITING

Tianjin, Tianjin Municipality, China
West China School of Medicine and West China Hospital Sichuan University
RECRUITING

Chengdu, Sichuan, China
Xi'an Central Hospital
RECRUITING

Xian, Shanxi, China
ZhongDa Hospital Southeast University
RECRUITING

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.